NCT06323213Not yet recruiting
Efficacy and Safety Study of 610 in Patients With Severe Asthma
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 3ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Asthma
- Drug/Device/Intervention
- 610
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Apr 01, 2024
- End date
- Sep 01, 2026
- Enrollment
- 480 participants
Primary outcome
Annualized rate of severe exacerbation events
Summary
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese
 adults with severe asthma.
ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06323213
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06323213 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and is currently Not yet recruiting. The study focuses on Asthma. Target enrollment is 480 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.